Late annual report notice, foreign filer
Open the filing on sec.gov
Kazia Therapeutics Limited (KZIA)
Nasdaq: KZIA · Pharmaceutical Preparations · filing with the SEC since 2002
The companyfiscal 2025, as filed
RevenueA$42,000-98.2%
Net income-A$20.7M+22.7%
Earnings per shareA$-0.04+62.8%
Operating cash flow-A$13.3M-38.6%
CashA$4.3M+162.2%
Debtn/a
Shareholders’ equity-A$8.3M+17.1%
Shares, diluted547.9M+107.8%
Return on equityn/a
The recordfrom its filings
Filings in 2026106
Newest filingNov 2 · NT 20-F
Annual reportNov 7, 2025
Quarterly reportn/a
Next report due20-F by Oct 28 · overdue
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted1
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in AUD. Nothing here is a forecast.
News
Large holder update, amended
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.